GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Piotroski F-Score

bluebird bio (bluebird bio) Piotroski F-Score : 4 (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

bluebird bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for bluebird bio's Piotroski F-Score or its related term are showing as below:

BLUE' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 4

During the past 12 years, the highest Piotroski F-Score of bluebird bio was 5. The lowest was 1. And the median was 3.


bluebird bio Piotroski F-Score Historical Data

The historical data trend for bluebird bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Piotroski F-Score Chart

bluebird bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 1.00 3.00 2.00 3.00

bluebird bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 4.00 4.00

Competitive Comparison of bluebird bio's Piotroski F-Score

For the Biotechnology subindustry, bluebird bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bluebird bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where bluebird bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was 32.232 + 21.24 + -72.908 + -71.731 = $-91.17 Mil.
Cash Flow from Operations was -56.273 + -86.638 + -72.725 + -61.846 = $-277.48 Mil.
Revenue was 0.063 + 2.381 + 6.89 + 12.392 = $21.73 Mil.
Gross Profit was 0.042 + -0.995 + -2.674 + 1.437 = $-2.19 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(520.098 + 554.902 + 692.736 + 663.393 + 613.608) / 5 = $608.9474 Mil.
Total Assets at the begining of this year (Sep22) was $520.10 Mil.
Long-Term Debt & Capital Lease Obligation was $232.02 Mil.
Total Current Assets was $247.08 Mil.
Total Current Liabilities was $158.96 Mil.
Net Income was -155.052 + -122.152 + -100.138 + -76.52 = $-453.86 Mil.

Revenue was 1.606 + 1.945 + 1.519 + 0.071 = $5.14 Mil.
Gross Profit was -2.075 + -6.365 + -0.226 + 0.071 = $-8.60 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(1339.644 + 593.795 + 491.071 + 573.592 + 520.098) / 5 = $703.64 Mil.
Total Assets at the begining of last year (Sep21) was $1,339.64 Mil.
Long-Term Debt & Capital Lease Obligation was $234.42 Mil.
Total Current Assets was $160.44 Mil.
Total Current Liabilities was $126.73 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

bluebird bio's current Net Income (TTM) was -91.17. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

bluebird bio's current Cash Flow from Operations (TTM) was -277.48. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-91.167/520.098
=-0.17528812

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-453.862/1339.644
=-0.33879299

bluebird bio's return on assets of this year was -0.17528812. bluebird bio's return on assets of last year was -0.33879299. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

bluebird bio's current Net Income (TTM) was -91.17. bluebird bio's current Cash Flow from Operations (TTM) was -277.48. ==> -277.48 <= -91.17 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=232.023/608.9474
=0.38102306

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=234.422/703.64
=0.33315616

bluebird bio's gearing of this year was 0.38102306. bluebird bio's gearing of last year was 0.33315616. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=247.076/158.957
=1.55435747

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=160.438/126.727
=1.26601277

bluebird bio's current ratio of this year was 1.55435747. bluebird bio's current ratio of last year was 1.26601277. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

bluebird bio's number of shares in issue this year was 109.098. bluebird bio's number of shares in issue last year was 81.543. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-2.19/21.726
=-0.10080088

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-8.595/5.141
=-1.67185372

bluebird bio's gross margin of this year was -0.10080088. bluebird bio's gross margin of last year was -1.67185372. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=21.726/520.098
=0.0417729

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=5.141/1339.644
=0.00383759

bluebird bio's asset turnover of this year was 0.0417729. bluebird bio's asset turnover of last year was 0.00383759. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

bluebird bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

bluebird bio  (NAS:BLUE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


bluebird bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of bluebird bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


bluebird bio (bluebird bio) Business Description

Traded in Other Exchanges
Address
455 Grand Union Boulevard, Somerville, MA, USA, 02145
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Executives
Richard A Colvin officer: Chief Medical Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain officer: President of SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk officer: Chief Financial Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima officer: Chief Commercial Officer, SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson director 85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio officer: Chief Business & Legal Officer C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman director 1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole officer: SVP, Secy. & General Counsel C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann officer: Chief Regulatory Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman officer: Chief Financial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten officer: Chief Accounting Officer 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145

bluebird bio (bluebird bio) Headlines

From GuruFocus

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

By Business Wire Business Wire 01-18-2023